
Lion Biotechnologies licenses tumor cell therapy technologies from Moffitt Cancer Center
Executive Summary
Lion Biotechnologies Inc. (cancer immunotherapies) licensed exclusive rights to two patent-pending tumor infiltrating lymphocyte (TIL) technologies from the University of South Florida’s H. Lee Moffitt Cancer Center & Research Institute. The license continues until the last patent related to the technologies expires, or 20 years, whichever comes first.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com